2015 Hot Print Markets Analysis: Target Verticals That Fit Your 'Sweet Spot'

No. 2 Medical/Pharma ($539B, +7 percent; with $15.5B to print, +4 percent) will return to vigor, while No. 7-ranked Health Providers ($3.545T, +pharma (+6 percent), long criticized for non-recoverable packaging. As no big pharma company grew in the last two years, 2015 is the recovery. Pfizer (+3 percent) will be buying pieces of competitors instead of selling parts of itself, and return—as all in the category must—to developing new drugs. Best positioned for print will be Glaxo Smithkline (+12 percent) as it surpasses Johnson & Johnson (+6 percent) in over-the-counter (OTC) products.

Most profound in healthcare is 3D printing, for which we as an industry must set up practice or otherwise perish. Ordered deposits of synthetic substrates and specific function inks are layered or weaved in-and-out of plane, much like a spider lays silk to create its web. Human and animal parts replacement will be the new medicine, eventually replacing chemical palliatives. Print, in this evolution, will rise to life though, to many, will fall on dead ears!